12-/6-04



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Xian Ming Zeng

Serial No.:

10/646,361

Filing Date:

August 21, 2003

Title:

INHALATION COMPOSITIONS WITH

HIGH DRUG RATIOS

Atty Docket No.:

NHC19587-USA

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL SHEET

Dear Sir:

Applicant hereby submits the Information Disclosure Statement with associated documents for filing in the above-referenced patent application. Applicant requests that the mailroom stamp and return the self-addressed postcard included with these documents.

If there are any questions, please call the undersigned at the telephone number indicated below.

Respectfully submitted,

Michael A. Steinberg, Ph.D. Registration Number 43,160

Attorney for Applicants

Cust. No. 42159 IVAX CORPORATION 4400 Biscayne Boulevard Miami, FL 33137

Tel.: (305) 575-6061 Fax.: (305) 575-6064

CERTIFICATE OF EXPRESS MAILING 37 C.F.R. § 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service in an envelope addressed to Commissioner for Patents, Alexandria, VA 22313-1450 on the date indicated below.

Express Mail No. EV 565698315 US

Date: December 15,2004

Sonia K. Kuster

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

DEC 1 5 2004

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known		
Application Number	10/646,361	
Filing Date	08/21/2003	
First Named Inventor	Xian Ming Zeng	
Art Unit	1616	
Examiner Name	Not yet assigned	
Attorney Docket Number	NHC19587-USA	

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.1	Number-Kind Code ^{2 (if known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevan Figures Appear
		^{US-} 3,957,965		Saxton Hartley et al	
_		^{US-} 3,994,974		Murakami et al	
		^{US-} 5,684,199		Francotte, Eric	
		^{US-} 6,199,607		Trofast, Jan	
		US-			-
		US-			
		US-			
70-11		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

Examiner Cite Initials* No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages		
•		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T
		WO 92/10229	06-07-2001	Novartis AG		
		WO 01/39745	06-25-1992	Norton Healthcare		
						L
						L
						L

Examiner	·	Date	
		Date	
Signature		Considered	
0.5		Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

DEC 1 5 2004 60

Sheet

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Hute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 2

	Complete if Known		
Application Number	10/646,361		
Filing Date	08/21/2003		
First Named Inventor	Xian Ming Zeng		
Art Unit	1616		
Examiner Name	Not yet assigned		
Attorney Docket Number	NHC19587-USA		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th Ed., McGraw Hill Companies Inc., New York 2001, pages 1701-1704	
		GENNARO, "Pharmaceutical Necessities", Remington's Pharmaceutical Sciences 18th Ed., MACK Publishing Co., Easton PA1990, pages 1286-1329	
		GENNARO, "Oral Solid Dosage Forms", Remington's Pharmaceutical Sciences 18th Ed., MACK Publishing Co., Easton PA1990, pages 1635-1638	
		O'CONNOR et al, "Powders", Remington: The Science and Practice of Pharmacy, 19th Ed., Lippincott, Williams & Wilkins1995, pages	
		ZENG et al, "Carrier Particles", Particulate Interactions In Dry Podwer Formulations for Inhalation, Taylor & Francis 2001 Pages 144-151	

Examiner		Date	
Signature	<u></u>	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.